Celecoxib increased cleaved caspase-3 expression from 18-50% in the tumors from the obese group as compared to 8-22% in the non-obese group, suggesting an enhanced effect of celecoxib on apoptosis in the setting of obesity. Here, CASP3 is linked to obesity due to melanocortin 4 receptor deficiency.